- Home
- HRMY vs SKWD Comparison
HRMY vs SKWD Comparison
Compare HRMY & SKWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SKWD
- Stock Information
- Founded
- HRMY 2017
- SKWD 2007
- Country
- HRMY United States
- SKWD United States
- Employees
- HRMY N/A
- SKWD N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SKWD Property-Casualty Insurers
- Sector
- HRMY Health Care
- SKWD Finance
- Exchange
- HRMY Nasdaq
- SKWD Nasdaq
- Market Cap
- HRMY 1.8B
- SKWD 2.3B
- IPO Year
- HRMY 2020
- SKWD 2023
- Fundamental
- Price
- HRMY $34.71
- SKWD $53.83
- Analyst Decision
- HRMY Strong Buy
- SKWD Buy
- Analyst Count
- HRMY 9
- SKWD 12
- Target Price
- HRMY $54.44
- SKWD $63.88
- AVG Volume (30 Days)
- HRMY 604.5K
- SKWD 437.8K
- Earning Date
- HRMY 08-05-2025
- SKWD 08-04-2025
- Dividend Yield
- HRMY N/A
- SKWD N/A
- EPS Growth
- HRMY 13.13
- SKWD 9.29
- EPS
- HRMY 2.62
- SKWD 2.98
- Revenue
- HRMY $744,852,000.00
- SKWD $1,213,759,000.00
- Revenue This Year
- HRMY $20.33
- SKWD $18.33
- Revenue Next Year
- HRMY $17.67
- SKWD $11.61
- P/E Ratio
- HRMY $12.97
- SKWD $18.05
- Revenue Growth
- HRMY 20.62
- SKWD 26.30
- 52 Week Low
- HRMY $26.47
- SKWD $34.10
- 52 Week High
- HRMY $41.61
- SKWD $65.05
- Technical
- Relative Strength Index (RSI)
- HRMY 63.75
- SKWD 30.91
- Support Level
- HRMY $33.76
- SKWD $53.27
- Resistance Level
- HRMY $35.08
- SKWD $55.38
- Average True Range (ATR)
- HRMY 0.91
- SKWD 1.87
- MACD
- HRMY 0.32
- SKWD -0.45
- Stochastic Oscillator
- HRMY 90.34
- SKWD 0.63
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.